Hemosphere™ HeRO™
  • Home
  • Medical Professionals
  • Patient Information
  • Implant Notification
  • Company
  • Find a Physician
  • Our Company

    • Management Team
      • Board of Directors
    • Mission Statement
    • Company Values
    • Compliance Program
      • Code of Conduct
        • Code Of Ethics Compliance
        • Company-Conducted Product Training and Education
        • Supporting Third Party Educational Conferences
        • Sales, Promotional and Other Business Meetings
        • Consulting Arrangements with Health Care Professionals
        • Prohibition on Entertainment and Recreation
        • Modest Meals Associated with Health Care Professional Business Interactions
        • Educational Items: Prohibition on Gifts
        • Provision of Coverage, Reimbursement and Health Economics Information
        • Research and Educational Grants and Charitable Donations
        • Evaluation and Demonstration Products
    • Careers
    • Contact Us
  • News

    • Business News
    • Upcoming Conferences
    • Clinical Presentations
      • Archives 2009
      • Archives 2008
      • Archives 2007
    • Publications
    • HeRO Graft Media
  • LOGIN

    • Log in
Board of Directors

James Bullock

CEO, Atritech (Independent Board Seat)

Tara Butler, MD

Ascension Health Ventures

Mitch Dann

Sapient Capital Management, LLC

Jon Osgood

Cutlass Capital, LLC

Dave Schulte

Kaiser Permanente Ventures

Edson Spencer Jr.

Affinity Capital (Lead Investor)

Bill Trainor

Mutual Capital Partners

 
INDICATIONS FOR USE: The HeRO Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. Rx Only. See instructions for use for full indication, contraindication and caution statements. Terms and Conditions. Privacy Policy. HeRO and Hemosphere are registered trademarks of Hemosphere, Inc. © 2012 Hemosphere, Inc. All Rights Reserved.